|
|
 |
|
Viewing report
|
|
|
|
R&D Trends: Influenza Vaccines - Commoditization Limits Opportunities in a Crowded Market
Datamonitor, Aug 2011, Pages: 53
In the last two post-pandemic years and with a number of seasonal influenza vaccines available, the race for novel influenza vaccine candidates has slowed somewhat. Pipeline candidates try to address further unmet needs, but novel technologies might struggle against the uncertainty regarding the next pandemic influenza strain and the increasing commoditization of the influenza markets.
Features and benefits
- Discussion of seasonal, pandemic and universal influenza vaccine pipelines
- Analysis of innovative new approaches in influenza vaccine development
- Discussion of clinical trial design and the target product profile (TPP) for influenza vaccines
- Analysis of future strategic opportunities and threats in a competitive influenza vaccine market
Highlights
- Novel products will further drive the commoditization of the influenza vaccine market and enhance the already fierce competition. It will also increase the pressure on innovative earlier-stage products such as DNA-based influenza vaccines which will have to show a clear benefit over existing products if they want to compete for market share.
- Datamonitor identified 22 compounds in the clinical seasonal influenza vaccine pipeline, with a diminishing number of later-stage products. With 28 candidates in development, the pandemic influenza vaccine pipeline is more robust. However, this also reflects the prevailing uncertainty about which strains are most likely to cause another pandemic.
- Pipeline influenza vaccines particularly try to address limitations associated with the amount of available vaccine, vaccine production timelines, strain coverage and vaccine efficacy. While a number of universal influenza vaccine candidates have reached clinical development, none has yet been able to progress beyond Phase II clinical trials.
Your key questions answered
- Get an overview of the pipelines for seasonal, pandemic and universal influenza vaccines
- Recognize development trends in influenza vaccines development and innovative earlier-stage approaches
- Understand opportunities and threats for influenza vaccine manufacturers and identify promising strategies to tackle future challenges
|
|
|
|
